NCT05812235Not yet recruiting
Bone Microstructure by Using HR-pQCT After Esophagectomy
Bone Microstructure by Using High-resolution Peripheral Quantitative Computed Tomography After Esophagectomy
Source: ClinicalTrials.gov · Last updated 24 Apr 2023 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Esophagectomy is most curative treatment to esophageal cancer. However, osteoporosis , which is characterized by both the loss of bone mass and the deterioration of bone architecture, is a serious complication in the long course after surgery. The aim of the present study was to evaluate osteoporosis by using high-resolution peripheral quantitative computed tomography (HR-pQCT) in the long course after esophagectomy. At least 3 years should have elapsed since operation without recurrence of esophageal cancer.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 118 (estimated)
- First submitted
- 2 Apr 2023
- Start date
- 25 May 2023
- Primary completion date
- 1 Mar 2026
- Lead sponsor
- Nagasaki University
- NCT number
- NCT05812235
What you commit to
- Study type: Observational
- Planned participants: 118
- From 25 May 2023 to the primary completion date, 1 Mar 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Radiotherapy
- Other diseases which affect bone metabolism Any disorder that, in the opinion of the investigator, may compromise the ability of the subject to give written informed consent and/or comply with study procedures Received \> 3 months (or equivalent) of osteoporosis treatment Currently enrolled in or has not yet completed at least 1 month since ending other investigational device or drug trial(s), or subject is receiving other investigational agent(s).
Other illness
- Present malignancy (except in situ carcinoma)
- Any condition that required chronic (greater than three months cumulative and greater than 5 mg/day) glucocorticoid therapy
Other
- Current use of the following osteoporosis agents; Teriparatide, Denosumab, and - -
- bisphosphonate
Who the study is looking for
- At least 3 years have elapsed since esophagectomy due to esophageal cancer
- Provide signed informed consent
Age in the registry: 50 years to 90 years · Sex: Male · Accepts healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.